|
1
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sharma A, O'Connor R, Celestino P, Killion
S, Griswold-Krupski L and Bansal-Travers M: Focus groups and
in-depth interviews to guide the development of lung cancer
screening informational materials. J Cancer Educ. Apr 20–2018.(Epub
ahead of print). doi: 10.1007/s13187-018-1362-4.
|
|
3
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang Z, Li J, Shen Q, Feng J, Liu H, Wang
W, Xu L, Shi G, Ye X, Ge M, et al: Contribution of upregulated
dipeptidyl peptidase 9 (DPP9) in promoting tumorigenicity,
metastasis and the prediction of poor prognosis in non-small cell
lung cancer (NSCLC). Int J Cancer. 140:1620–1632. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang F, Wei K, Qin Z, Liu W, Shao C, Wang
C, Ma L, Xie M, Shu Y and Shen H: miR-598 suppresses invasion and
migration by negative regulation of Derlin-1 and
epithelial-mesenchymal transition in non-small cell lung cancer.
Cell Physiol Biochem. 47:245–256. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang JZ, Bian L, Hou JG and Wang HY:
miR-550a-3p promotes non-small cell lung cancer cell proliferation
and metastasis through down-regulating TIMP2. Eur Rev Med Pharmacol
Sci. 22:4156–4165. 2018.PubMed/NCBI
|
|
7
|
Huang Y, Wu Y, Dong J, Han D, Yang S and
Jiang L: MicroRNA-133a-3p exerts inhibitory effects on gallbladder
carcinoma via targeting RBPJ. Am J Cancer Res. 6:2448–2462.
2016.PubMed/NCBI
|
|
8
|
Gao SH, Liu J, Zhang HJ, Zhao N and Zhang
J: Low miR-133a expression is a predictor of outcome in patients
with esophageal squamous cell cancer. Eur Rev Med Pharmacol Sci.
20:3788–3792. 2016.PubMed/NCBI
|
|
9
|
Wang Y, Li J, Chen H, Mo Y, Ye H, Luo Y,
Guo K, Mai Z, Zhang Y, Chen B, et al: Down-regulation of miR-133a
as a poor prognosticator in non-small cell lung cancer. Gene.
591:333–337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai J, Liu T, Huang P, Yan W, Guo C, Xiong
L and Liu A: USP39, a direct target of microRNA-133a, promotes
progression of pancreatic cancer via the AKT pathway. Biochem
Biophys Res Commun. 486:184–190. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI,
Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, et al:
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as
a critical signal for tumor growth. Oncogene. 32:5429–5438. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Je DW, O YM, Ji YG, Cho Y and Lee DH: The
inhibition of SRC family kinase suppresses pancreatic cancer cell
proliferation, migration, and invasion. Pancreas. 43:768–776. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sato A, Sekine M, Virgona N, Ota M and
Yano T: Yes is a central mediator of cell growth in malignant
mesothelioma cells. Oncol Rep. 28:1889–1893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iida M, Brand TM, Campbell DA, Li C and
Wheeler DL: Yes and Lyn play a role in nuclear translocation of the
epidermal growth factor receptor. Oncogene. 32:759–767. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seki T, Fujii G, Mori S, Tamaoki N and
Shibuya M: Amplification of c-yes-1 proto-oncogene in a primary
human gastric cancer. Jpn J Cancer Res. 76:907–910. 1985.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang B, Sun L, Li J and Jiang R: miR-577
suppresses cell proliferation and epithelial-mesenchymal transition
by regulating the WNT2B mediated Wnt/β-catenin pathway in non-small
cell lung cancer. Mol Med Rep. 18:2753–2761. 2018.PubMed/NCBI
|
|
18
|
Han L, Chen W, Xia Y, Song Y, Zhao Z,
Cheng H and Jiang T: miR-101 inhibits the proliferation and
metastasis of lung cancer by targeting zinc finger E-box binding
homeobox 1. Am J Transl Res. 10:1172–1183. 2018.PubMed/NCBI
|
|
19
|
Sui Y, Zhang X, Yang H, Wei W and Wang M:
MicroRNA-133a acts as a tumour suppressor in breast cancer through
targeting LASP1. Oncol Rep. 39:473–482. 2018.PubMed/NCBI
|
|
20
|
Li W, Chen A, Xiong L, Chen T, Tao F, Lu
Y, He Q, Zhao L, Ou R and Xu Y: miR-133a acts as a tumor suppressor
in colorectal cancer by targeting eIF4A1. Tumour Biol.
39:10104283176983892017.PubMed/NCBI
|
|
21
|
Sun L, Guo Z, Sun J, Li J, Dong Z, Chen J,
Kan Q and Yu Z: miR-133a acts as an anti-oncogene in hepatocellular
carcinoma by inhibiting FOSL2 through TGF-beta/Smad3 signaling
pathway. Biomed Pharmacother. 107:168–176. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li C, Li X, Gao S, Li C and Ma L:
MicroRNA-133a inhibits proliferation of gastric cancer cells by
downregulating ERBB2 expression. Oncol Res. 25:1169–1176. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Wang Y and Li YZ: MicroRNA-133a
suppresses the proliferation, migration, and invasion of laryngeal
carcinoma cells by targeting CD47. Tumour Biol. 37:16103–16113.
2016. View Article : Google Scholar
|
|
24
|
Farazi TA, Juranek SA and Tuschl T: The
growing catalog of small RNAs and their association with distinct
Argonaute/Piwi family members. Development. 135:1201–1214. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou GQ, Han F, Shi ZL, Yu L, Li XF, Yu C,
Shen CL, Wan DW, Zhu XG, Li R, et al: miR-133a-3p targets
SUMO-specific protease 1 to inhibit cell proliferation and cell
cycle progress in colorectal cancer. Oncol Res. 26:795–800. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong X, Su H, Jiang F, Li H, Shi G and Fan
L: miR-133a, directly targeted USP39, suppresses cell proliferation
and predicts prognosis of gastric cancer. Oncol Lett. 15:8311–8318.
2018.PubMed/NCBI
|
|
27
|
Garmendia I, Pajares MJ, Hermida-Prado F,
Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K,
Moreno H, et al: YES1 drives lung cancer growth and progression and
predicts sensitivity to dasatinib. Am J Respir Crit Care Med. Jun
5–2019.(Epub ahead of print). doi: 10.1164/rccm.201807-1292OC.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fang Z, Yin S, Sun R, Zhang S, Fu M, Wu Y,
Zhang T, Khaliq J and Li Y: miR-140-5p suppresses the
proliferation, migration and invasion of gastric cancer by
regulating YES1. Mol Cancer. 16:1392017. View Article : Google Scholar : PubMed/NCBI
|
